Ribozyme, Eli Lilly deal

RZYM repurchased from LLY rights to its Heptazyme (LY466700) synthetic ribozyme against hepatitis C virus (HCV) (see BioCentury, March 29, 1999). RZYM recently reported preliminary Phase I results showing the product was well tolerated (see BioCentury, Sept. 18). RZYM expects to begin in the first quarter of 2001 Phase II testing of Heptazyme monotherapy, with higher doses than used in Phase I, and combination therapy with interferon, in HCV-infected patients. ...